Agile raises $45M for contraceptive patch trials

Agile Therapeutics pulled the wraps off a $45 million Series B preferred stock financing this morning--the company's first financing round since it landed $17.6 million in 2007. The funding will allow Agile to complete Phase III clinical development and file for marketing approval for its low-dose, weekly contraceptive patch AG200-15. The company will also advance AG1000, its progestin-only contraceptive patch for breastfeeding mothers, into Phase II clinical...